Elrexfio (elranatamab-bcmm) / Pfizer - LARVOL DELTA

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3 (ASH 2025) - P2 | "Furthermore, these data support thefeasibility of dose interruptions to manage adverse events and allow for treatment breaks withoutcompromising the efficacy of ELRA. Studies evaluating the possibility of restarting ELRA upon signs ofdisease progression are warranted."

Retrospective data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Respiratory Diseases • Septic Shock

IMMUNOTHERAPY UNDER THE MICROSCOPE: CARDIO-RENAL OUTCOMES OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CART) VS BISPECIFICS IN A REAL-WORLD PROPENSITY-MATCHED COHORT STUDY (ACC 2026) - "Background: No current large studies directly compare cardiac outcomes of bispecific antibodies (Teclistamab, Elranatamab, Talquetamab, Blinatumomab, Epcoritamab, Mosunetuzumab) and CAR T-cell therapies. CART therapy was associated with lower all-cause mortality and fewer cardiac and renal adverse events compared to bispecific antibodies, supporting its potential cardio-oncology safety advantage. Further prospective studies are warranted to validate these findings."

Bispecific • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cardiovascular

Dermatologic adverse events with bispecific T-cell engager therapies (AAD 2026) - " Among solid-tumor-directed BiTEs, tebentafusp dAEs include early, diffuse exanthems with pruritus, xerosis, edema, and bullous changes in high-grade events (dAE 83-91%; pruritus 69%; grade ≥3 rash 16-21%); delayed depigmentation/vitiligo-like changes are also reported. Tarlatamab presents with low-grade morbilliform eruptions (rash 6%, grade ≥3 2%; pruritus 11%). Among BiTEs for hematologic malignancies, talquetamab results in a distinctive mucocutaneous dAE profile involving hand-foot syndrome, nail changes (56%) including onychomadesis and onychodystrophy, dysgeusia (72%), and xerostomia (36%); dAE-related discontinuation is <1%. Mosunetuzumab leads to rash in 34-39% (grade ≥3 4%) and injection-site reactions in 53%. With blinatumomab, infusion-type exanthems predominate (7-16%; ≥ grade 3 ~1%); medium-vessel vasculitis and peri/subungual pyogenic granulomas have also occurred. For elranatamab, injection-site reactions (37%) and secondary cutaneous malignancies..."

Adverse events • Bispecific • IO biomarker • Dental Disorders • Hematological Malignancies • Immunology • Pruritus • Skin Cancer • Solid Tumor • Vasculitis • Vitiligo • Xerostomia

Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study. (PubMed, Clinicoecon Outcomes Res) - "Early RW data on elranatamab administration and vial usage in patients with MM in Japan suggest that dosing is generally aligned with label expectations, with variable dosing during QW and Q2W maintenance for some patients. Projected vial usage in this RW setting was lower than the expected usage per label."

HEOR • Journal • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

ELRANATAMAB IN COMBINATION WITH DARATUMUMAB AND LENALIDOMIDE (EDR) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NOT ELIGIBLE FOR TRANSPLANT: INITIAL RESULTS FROM MAGNETISMM-6 PART 1 (EHA 2025) - P3 | "MagnetisMM-6 (NCT05623020) is a phase 3, open-label, randomized study evaluating the efficacy and safety of ELRA in combination with lenalidomide (R) ± daratumumab (DARA) (EDR or ER) vs DARA + R + dexamethasone (DRd) in patients with transplant-ineligible (TI) NDMM. In patients with TI NDMM, EDR demonstrated a manageable safety profile consistent with the known toxicities of components. High response rates and early responses were observed. Enrollment in dose level H evaluating the ER combination is ongoing."

Clinical • Combination therapy • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Transplantation

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial. (PubMed, J Hematol Oncol) - "All patients received BCMA/GPRC5D bispecific CAR T-cell therapy after bridging therapy with localized radiotherapy or Elranatamab...Median OS and PFS were not reached. Collectively, these findings highlight a potential therapeutic strategy involving BCMA/GPRC5D dual-targeted CAR T-cell therapy for patients with aggressive forms of multiple myeloma, particularly those with extramedullary disease, and support the need for further exploration and validation in larger, multi-center clinical studies."

Journal • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukopenia • Multiple Myeloma • Oncology • Thrombocytopenia

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial (ASH 2025) - P1, P2 | "The study continuesenrolling and will explore ELRA + IBER in a larger group of pts with RRMM. Results from a longer follow-up will be presented."

Clinical • Combination therapy • P1 data • Anorexia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study. (PubMed, Target Oncol) - "These findings support individualized treatment selection; prospective comparative trials are warranted."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. (PubMed, Eur J Haematol) - "Overall, elranatamab represents a valuable addition to the therapeutic armamentarium for RRMM. Ongoing studies and real-world experience will be critical to refine its positioning, identify patients most likely to benefit, and define its role in combination strategies."

Journal • Review • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Renal Disease

Characterizing the risk of infections with T-cell engagers in multiple myeloma (AACR 2026) - "Here, we report our experience with infectious complications in relapsed/refractory MM pts receiving TCEs, characterizing their incidence, severity and risk factors. This is a single-center retrospective study of 79 consecutive MM pts who received teclistamab (Tec), elranatamab (Elra) or talquetemab (Talq) between 1/2023-9/2025. In this single-center analysis of heavily pretreated MM pts receiving TCEs, infectious complications were frequent, occurring in 61% pts. Infections were independently associated with inferior OS, while use of IVIG was associated with a 72% reduction in risk of death. Prospective studies are required to establish optimal timing and use of IVIG to demonstrate its efficacy in pts receiving TCEs."

Hematological Malignancies • Multiple Myeloma • Oncology

A universal multi-receptor NK cell platform engineered for synergistic combination with antibody and T-cell engager therapies (AACR 2026) - "This dual-activation system allows PluraliNK cells to respond to CD3- or CD16-mediated signals and to pair with diverse mAbs or TCEs without further modification. PluraliNK cells showed potent cytotoxicity across hematologic and solid tumor models when combined with approved mAbs (rituximab, trastuzumab) or TCEs (blinatumomab, glofitamab, elranatamab), consistently outperforming mAb/TCE monotherapy or unmodified NK cells. This universal NK-cell platform enables multiantigen targeting and integration with existing mAbs and TCEs, addressing tumor heterogeneity and immune escape without requiring antigen-specific CAR redesign. A first-in-human clinical trial of PluraliNK cells with antibody therapy has been initiated."

First-in-human • Oncology • Solid Tumor • FCGR3A • IL15

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. (clinicaltrials.gov) - P4 | N=400 | Not yet recruiting | Sponsor: Anne Louise Tølbøll Sørensen

New P4 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

CARDIOVASCULAR SAFETY SIGNALS OF BISPECIFIC ANTIBODIES: INSIGHTS FROM FAERS DATABASE (ACC 2026) - " FAERS (2017-2023) was queried for blinatumomab, teclistamab, talquetamab, elranatamab, epcoritamab, and glofitamab. Bispecific antibodies exhibit distinct cardiovascular safety signals: elranatamab, epcoritamab, and glofitamab with heart failure; epcoritamab with atrial fibrillation and myocardial infarction; and teclistamab with tachycardia. These findings emphasize the need for cardiovascular monitoring during therapy, particularly in patients with pre-existing risk."

Bispecific • Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Myocardial Infarction

CARDIOVASCULAR ADVERSE EVENTS ASSOCIATED WITH BI-SPECIFIC T-CELL ENGAGER THERAPY (ACC 2026) - "Coronary artery disease was the strongest predictor, with elevated risk also linked to multiple myeloma, prior anthracyclines, and elranatamab. BiTE therapy shows a favorable cardiovascular safety profile, but patients with coronary artery disease warrant careful evaluation before and during treatment."

Adverse events • Bispecific • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Hematological Malignancies • Multiple Myeloma

Gastrointestinal (GI) Pathology Findings in Patients Receiving Bispecific T-cell Engagers (BiTEs) (USCAP 2026) - "Four received CD38 BiTE (elranatamab: 3; teclistimab: 1) for multiple myeloma and 1 received CD20 BiTE (epcoritamab) for B-cell lymphoma. Gastrointestinal BiTE-related injury can be associated with neutrophilic inflammation, intraepithelial lymphocytosis, and/or increased crypt apoptosis, as well as absence of the target cell populations. Patients often have comorbidities, highlighting the need for clinicopathologic correlation. One patient with BiTE-colitis responded to steroids and also had CRS and ICANS, suggesting drug-induced systemic immune activation."

Bispecific • Clinical • B Cell Lymphoma • Colorectal Adenocarcinoma • Colorectal Cancer • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Pneumonia • Rectal Adenocarcinoma • Respiratory Diseases • Septic Shock • Solid Tumor • CD20 • SDC1

EPIC: Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Massachusetts General Hospital | Trial primary completion date: Dec 2025 ➔ Aug 2026

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

ELISA in Relapsed/Refractory MM (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

CMV Reactivation With Bispecific Antibodies in Multiple Myeloma (HOPA 2026) - " This multicenter, retrospective review included 555 patients who received teclistamab, elranatamab, or talquetamab...Age, the number of previous lines of therapy, previous BCMA-directed therapy, maximum-grade cytokine release syndrome, tocilizumab treatment, dexamethasone treatment, use of IVIG, and IgG levels at day 30 and day 90 were evaluated via logistic regression; none of the above factors predicted CMV reactivation. CMV reactivation occurred in almost 25% of patients who are CMV seropositive and receiving bispecific antibodies for RRMM, with 33% of those patients requiring CMV-directed therapy. This incidence reflects the need for additional guidance for risk stratification, monitoring, and prophylactic strategies in this high-risk patient population."

Late-breaking abstract • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Outcomes of Supportive Care Versus Pharmacologic Intervention for the Management of CRS in Relapsed or Refractory Multiple Myeloma Treated With BCMA- and GPRC5D-Directed Bispecifics (HOPA 2026) - " This retrospective study included 555 patients with relapsed or refractory multiple myeloma from 7 US academic centers that initiated elranatamab, teclistamab, or talquetamab by March 2025...Recurrent CRS in all groups was at the same or lower grade, except for 1 patient who received dexamethasone and tocilizumab and had grade 1 CRS with SUD 1 and grade 2 CRS with SUD 2. Supportive care alone demonstrated similar outcomes to pharmacologic intervention for low-grade CRS, particularly grade 1, which supports its role as a safe, effective initial management strategy that may limit the need for additional intervention."

Late-breaking abstract • Hematological Malignancies • Inflammation • Multiple Myeloma

The evolution of bispecific antibodies in multiple myeloma. (PubMed, Chin Clin Oncol) - "The treatment of multiple myeloma (MM) has revolutionized over the last decade with the advent of CD38-targeting monoclonal antibodies such as daratumumab and isatuximab that were integrated into the therapeutic arsenal of patients with newly diagnosed or with relapsed and/or refractory (R/R) MM...Four BsAbs-teclistamab, elranatamab, linvoseltamab, and talquetamab-are currently approved by the Food and Drug Administration (FDA) for the management of patients with R/R MM. We review in this paper the most studied BiAbs, their mechanism of action, clinical activity, the mechanism of resistance. We discuss the place of BiAbs in the therapeutic arsenal of MM and the emergence of novel strategies such as combining two classes of BiAbs (for example teclistamab and talquetamab) or novel therapies such as trispecific antibodies to overcome resistance and increase the efficacy of BiAbs."

Journal • Review • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

SWE-DISCO-MM1: Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment (clinicaltrialsregister.eu) - P1/2 | N=200 | Not yet recruiting | Sponsor: Vaestra Goetalandsregionen

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center

New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN'S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN (ISPOR 2026) - "Elranatamab represents a cost-effective treatment option compared to PCT from the Japanese payer perspective. These findings provide valuable evidence to support future decision-making and policy discussions regarding the health economic impact of TCE MM in Japan."

Cost effectiveness • HEOR • Hematological Malignancies • Multiple Myeloma

CA057-1040: Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma (clinicaltrialsregister.eu) - P1/2 | N=24 | Recruiting | Sponsor: Celgene Corp.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Indirect comparison of linvoseltamab (LINVO) versus elranatamab (ELRA) for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) (DKK 2026) - "These results highlight the potential of LINVO as a highly effective treatment option for TCE RRMM."

Hematological Malignancies • Multiple Myeloma